click below
click below
Normal Size Small Size show me how
Dyslipidemias LPN
LPN GOODCARE 2018 Dyslipidemias
| Question | Answer |
|---|---|
| characterized by fatty deposits in artery walls | Atherosclerosis |
| Abnormal elevation of cholesterol and triglycerides | Hyperlipidemia |
| Caused by genetic abnormalities and secondary factors such as lifestyle, drugs, or underlying diseases | Hyperlipidemia |
| 30 minutes of moderate daily exercise is recommended. A fasting lipoprotein profile (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides) is recommended every 5 years for all adults older than 20 years of age | Patient education Hyperlipidemia |
| Consume high-bulk foods: whole grains, raw fruits and vegetables and Lots of water to minimize constipation Avoid high-cholesterol foods: liver, egg yolks, meats, fried foods, fatty desserts, nuts Importance of weight reduction and exercise Lifestyle c | Patient education Hyperlipidemia |
| Weight reduction Exercise Diet low in cholesterol and fat | PrimaryTreatment of Hyperlipidemias |
| Presence of coronary artery disease (CAD) Level of total cholesterol Level of HDL-C Success of diet interventions | NCEP Treatment of Hyperlipidemias |
| Best administered at night because of peak cholesterol production at this time. Do not differ in effectiveness, but they do differ in potential drug interactions. | Statins |
| Grapefruit juice inhibits the metabolism and should be avoided | Statins |
| Inhibit enzyme responsible for converting HMG-CoA to mevalonate, ultimately reduce liver cholesterol | Statins |
| Used In conjunction with dietary therapy to reduce LDL and total cholesterol levels | Statins |
| Headaches; nausea, abdominal bloating, gas | Statins Common adverse effects |
| Liver dysfunction; myopathy, rhabdomyolysis; myoglobinuria | Serious adverse effects Statins Liver dysfunction; myopathy, rhabdomyolysis; myoglobinuria |
| muscle aches, soreness, and weakness | Myopathy: early signs are m |
| kidney damage resulting from progressing myopathy (may have pinkish- or red-tinged urine) | Rhabdomyolysis |
| Liver function should be monitored. If AST, ALT rise to 3X normal, medication should be discontinued | Statins |
| Myopathy may occur if used in conjunction with statins. | Fibric Acids |
| Most effective agents in lowering triglycerides | Fibric Acids |
| Serious adverse effects: early symptoms of gallbladder disease and hepatotoxicity. | Fibric Acids |
| gemfibrozil (Lopid), fenofibrate (Tricor | Fibric Acids |
| Lower triglyceride levels; mechanism of action unknown | Fibric Acids |
| Used In conjunction with dietary therapy to treat hypertriglyceridemia | Fibric Acids |
| Common adverse effects Nausea, diarrhea, flatulence, bloating, abdominal distress | Fibric Acids |
| Serious adverse effects Fatigue, anorexia, nausea, malaise, jaundice | Fibric Acids |
| ezetimibe (Zetia) | Miscellaneous Antilipemic Agents |
| Block absorption of cholesterol from small intestine | ezetimibe (Zetia) |
| Used conjunction with dietary therapy to decrease elevated cholesterol | ezetimibe (Zetia) |
| Antilipemic agent whose Common adverse effects are Abdominal pain, diarrhea | ezetimibe (Zetia) |
| The first drug in this class and should not be used with fibric acid | Ezetimibe |
| Often referred to as fish oils | omega-3 fatty acids (Lovaza) |
| Actions Reduce synthesis of triglycerides in the liver; mechanism of action unknown | omega-3 fatty acids (Lovaza) |
| New class of agents to reduce atherosclerosis | omega-3 fatty acids (Lovaza) |
| Used in conjunction with dietary therapy to decrease elevated triglyceride levels | omega-3 fatty acids (Lovaza) |
| Common adverse effects Nausea, back and abdominal pain, bloating, bad taste in mouth, weakness, diarrhea | omega-3 fatty acids (Lovaza) |
| Use with caution in patients who are sensitive or allergic to fish | omega-3 fatty acids (Lovaza) |
| Advantage over fibrates and niacin is that they do not cause myositis or rhabdomyolysis when combined with statins | omega-3 fatty acids (Lovaza) |